The White House has ordered the National Institutes of Health (NIH) to study "regret" among transgender people who have ...

A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...

During the fourth quarter, the Harbor Health Care ETF returned –10.89%, underperforming the Russell 3000 Growth Health Care ...

To prevent dominance by an acknowledged adversary, the National Security Commission on Emerging Biotechnology (NSCEB) calls ...

Experts say the layoffs are already causing issues in drug development — and things may get far worse without critical ...

Biotechnology will have a transformative impact on defense, supply chains, agriculture, health and computing, all areas that ...

Nebraska Sen. Pete Ricketts told reporters on Wednesday that he would not be signing onto Iowa Sen. Chuck Grassley’s bill that aims to add Congressional oversight to tariffs while defending the ...

Gene therapy for cystic fibrosis is advancing fast. Explore key biotech players, clinical progress, and its potential to ...

The U.S. National Security Commission on Emerging Biotechnology (NSCEB) is urging Congress to reinvest in American biotechnology because “the U.S. is dangerously close to falling behind China,” ...

China has pulled ahead of the United States in key areas of the life sciences, and the U.S. may only have a handful of years ...

The exemption may be short-lived if President Trump makes good on threats to use tariffs as leverage to bring drug production ...

Learn more about whether Moderna, Inc. or TG Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.